Autolus Therapeutics (NASDAQ:AUTL) Rating Increased to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Autolus Therapeutics from “strong sell” to “sell,” while broader analyst sentiment remains more positive with a “Moderate Buy” consensus and an average price target of $8.75.
• AUTL opened at $2.11, with a 52-week range of $1.17 to $2.52 and a market capitalization of approximately $561.6 million. The company remains unprofitable, reporting a negative net margin of 311.98% and analysts forecasting a full-year loss of $0.86 per share.
• Institutional investors own approximately 72.83% of the company, with several hedge funds and investment managers increasing their positions in Autolus during recent quarters.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

Other analysts have also recently issued research reports about the stock. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings lowered Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 31st. Finally, Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.75.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $2.11 on Friday. Autolus Therapeutics has a one year low of $1.17 and a one year high of $2.52. The company has a market cap of $561.60 million, a PE ratio of -1.94 and a beta of 2.07. The firm's 50 day simple moving average is $1.59 and its 200 day simple moving average is $1.54.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million during the quarter, compared to analysts' expectations of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. Equities research analysts expect that Autolus Therapeutics will post -0.86 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mak Capital One LLC increased its position in shares of Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company's stock worth $59,711,000 after buying an additional 3,987,727 shares during the period. Armistice Capital LLC boosted its position in Autolus Therapeutics by 12.2% during the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company's stock valued at $34,825,000 after acquiring an additional 1,900,000 shares during the last quarter. Syncona Portfolio Ltd bought a new stake in Autolus Therapeutics during the second quarter valued at $26,625,152,000. Schroder Investment Management Group grew its holdings in Autolus Therapeutics by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company's stock worth $18,694,000 after acquiring an additional 1,056,092 shares during the period. Finally, Bank of America Corp DE grew its holdings in Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company's stock worth $3,308,000 after acquiring an additional 1,054,458 shares during the period. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source